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Abstract: The blood-brain barrier (BBB) impedes the influx of intravascular compounds from the blood to the brain. Few 
blood-borne macromolecules are transferred into the brain because vesicular transcytosis in the endothelial cells is consid-
erably limited and the tight junction is located between the endothelial cells. At the first line of the BBB, the endothelial 
glycocalyx which is a negatively charged, surface coat of proteoglycans, and adsorbed plasma proteins, contributes to the 
vasculoprotective effects of the vessels wall and are involved in maintaining vascular permeability. In the endothelial cy-
toplasm of cerebral capillaries, there is an asymmetrical array of metabolic enzymes such as alkaline phosphatase, acid 
phosphatase, 5’-nucleotidase, adenosine triphosphatase, and nucleoside diphosphatase and these enzymes contribute to in-
activation of substrates. In addition, there are several types of influx or efflux transporters at the BBB, such as P-
glycoprotein (P-gp), multidrug resistance associated protein, breast cancer resistance protein, organic anion transporters, 
organic cation transporters, organic cation transporter novel type transporters, and monocarboxylic acid transporters. P-gp, 
energy-dependent efflux transporter protein, is instrumental to the barrier function. Several findings recently reported in-
dicate that endothelial P-gp contributes to efflux of undesirable substances such as -amyloid protein from the brain or 
periarterial interstitial fluid, while P-gp likely plays a crucial role in the genesis of multiple vascular abnormalities that ac-
company hypertension. In this review, influx and efflux mechanisms of drugs at the BBB are also reviewed and how 
medicines pass the BBB to reach the brain parenchyma is discussed. 
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1. INTRODUCTION 
  The mammalian brain restricts the entrance of ions and 
solutes circulating in the bloodstream by the blood-brain 
barrier (BBB) [13]. The BBB is built up by a monolayer of 
endothelial cells (ECs) lining the brain capillaries that re-
stricts the movement of small polar molecules and macro-
molecules between the blood and the brain interstitial fluid 
with tight junctions between ECs [12,65,88]. The endothelial 
barrier is supplemented with capillary pericytes that share 
the basement membrane with the ECs. Moreover, the astro-
cyte perivascular end-feet almost totally cover the abluminal 
surface of the microvascular basement membrane (Fig. 1). 
  The brain capillaries were characterized morphologically 
as the site of the BBB by Reese and Karnovsky [65] after 
introduction of electron microscopy and the use of horserad-
ish peroxidase as a macromolecular tracer. Further ultra-
structural studies revealed that the continuous endothelium 
of brain capillaries possesses several unique structural and 
functional features [11,85,86,89]. 
  In this review, not only ultrastructural features at the 
BBB but also functional expression of several transporters 
such as P-gp are discussed. Information on transportation of 
blood-borne substances from the bloodstream to the brain 
parenchyma will be useful to understand how medicines are 
taken into the brain. 
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2. MOLECULAR ANATOMY IN THE BRAIN ENDO-
THELIAL CELL BARRIER 
2.1. Tight Junctions (TJ) 
  Junctional complexes in the ECs of cerebral capillaries 
are comprised of TJ and adherens junctions (AJ) (Fig. 1). 
The TJs ultrastructurally appear as sites of apparent fusion 
involving the outer leaflets of the plasma membrane [14, 
41,54]. The TJ consists of three integral membrane proteins, 
namely, claudin, occludin, and junction adhesion molecules, 
and a number of cytoplasmic accessory proteins including 
zonula occludens (ZO)-1, ZO-2, ZO-3, cingulin, and others 
[20,33,34]. AJs are composed of a cadherin-catenin complex 
and its associated proteins. Cytoplasmic proteins link mem-
brane proteins to actin, which is the primary cytoskeleton 
protein in the maintenance of the structural and functional 
integrity of the endothelium.  
2.2. Molecules in the Transcytotic Pathway for Blood-
Borne Proteins 
  Non-lipid-soluble micromolecules and macromolecules 
are capable of circumventing the “fluid-brain barrier” by 
intracellular routes related to three separate and distinct en-
docytic processes [15,16], namely, (a) fluid-phase endocyto-
sis, (b) adsorptive endocytosis, and (c) receptor-mediated 
endocytosis. (a) Fluid-phase endocytosis is a constitutive 
process for acquiring extracellular macromolecules and re-
cycling of the plasma membrane. This internalization proc-
ess occurs indiscriminately and without binding to the cell 
surface [16]. (b) Adsorptive endocytosis concerns molecules 
such as lectins that bind to carbohydrate moieties on the cell 
surface (e.g., wheat germ agglutinin), and positively charged 
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surface components. (c) Receptor-mediated endocytosis has 
been identified in clathrin-coated vesicles with the binding of 
a ligand (e.g., insulin, transferrin) to a cell surface receptor 
specific for that ligand; the binding then triggers the inter-
nalization of the receptor-ligand complex. Clathrin-mediated 
endocytosis from the plasma membrane allows cells to inter-
nalize proteins and other biomolecules from their environ-
ment  via specific receptors. Receptors are endocytosed by 
their capture in clathrin-coated vesicles budding from the 
plasma membrane. In addition, vesiculo-vacuolar organelle 
[42] and vesiculo-tubular structures [51,77] have been sug-
gested as transendothelial pathways for macromolecular ex-
travasation. 
3. ULTRASTRUCTURAL CYTOCHEMISTRY OF 
ENZYMATIC AND NON-ENZYMATIC CONSTITU-
ENTS OF BRAIN ENDOTHELIA 
3.1. Enzymatic Activity 
  Distribution patterns of several activity detected by en-
zymatic histochemistry in fixed samples have been reported. 
(a) Alkaline Phosphatase (ALPase) 
  It is well known that ALPase is a nonspecific enzyme 
and can hydrolyze various phosphate esters both organic and 
inorganic, like -naphthyl phosphate, p-nitrophenyl phos-
phate, AS-naphthols, etc. In the majority of animal species 
including mammals, the ECs of the brain microvessels of 
BBB type show a high acivity of ALPase. The ultrastructural 
localization of the reaction product for ALPase activity is 
different in brain as compared to muscle capillary endothelia 
[90]. In capillary ECs of mice, the positive reaction appears 
on the blood-oriented surface of the luminal plasma mem-
brane. On the contrast, in the arterioles, the reaction product 
is present on both sides (luminal and abluminal) of the ECs 
[88]. In guinea pig [40], a positive reaction for ALPase ap-
pears on both luminal and abluminal fronts of the ECs in 
brain capillaries. The localization of the ALPase is changed 
in pathological conditions induced by chronic relapsing ex-
perimental allergic encephalomyelitis.  
(b) Acid Phosphatase (ACPase) 
  ACPase is a typical lysosomal enzyme considered to be 
an excellent enzymatic marker of these organelles [60] and is 
negligible in normal brain ECs. It can play an important 
emergency role in pathological and abnormal conditions as 
one of the digestive enzymes of the lysosomal system pre-
sent in great abundance in perivascular cells. 
(c) 5’-Nucleotidase (5’-N) 
  It is a generally accepted view that 5’-N is a typical 
plasmalemmal enzyme, and its activity has been used as a 
marker of purity of the isolated plasma membrane fractions 
[9]. 5’-N is transmembrane glycoprotein with sugar residues 
and the transmembrane location of the enzyme is typical for 
transport enzymes with hydrolytic sites. Because phos-
phorylytic cleavage of adenosine-5’-phosphate is necessary 
for the uptake of adenosine and for facilitation of its trans-
port across the cell membrane [6], the importance of 5’-N in 
this processes is generally acknowledged.  
(d) Adenosine Triphosphatase - Na
+,K
+-ATPase – 
  The enzymatic activity of ATPase appears mainly in the 
cell membranes. It is very sensitive to aldehyde fixatives and 
accordingly controversial findings have been reported. In 
some cases, the ATPase is activated by Mg
2+, in some by 
Ca
2+, and in other cases by both Ca
2+ and Mg
2+. Na
+,K
+-
ATPase is the ouabain-sensitive sodium pomp that concen-
trates potassium in the cytoplasm and deplete intracellular 
sodium. The results of several observations indicated a dis-
tribution pattern of the enzymatic activity of Na
+, K
+-
ATPase, mainly on the abluminal side of the ECs of the rat 
brain capillary was observed by Firth [28] and by Betz et al.
[7], while other authors [38,39] did not find a positive reac-
tion for ATPase in the rat brain capillaries after incubation in 
Fig. (1). Blood-brain barrier and the tight junction. (A) Schematic outline of a capillary of the blood-brain barrier in a transverse section 
showing the endothelium with a tight junction, basement membrane, a pericyte, and astrocytes. The localization of a gap junction between 
end-feet of the astrocytes is conceptually shown. (B) An electron micrograph showing a typical mammalian endothelial cell combined with a 
tight junction (arrows) and cationized ferritin (arrowheads) bound to the luminal endothelial surface representing the endothelial glycocalyx. 
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a Mayahara medium. It is likely that the enzymatic activity 
of Na
+, K
+-ATPase present in the wall of brain microvessels, 
especially in the membranes adjacent to the basement mem-
brane. Thus, Na
+, K
+-ATPase would be responsible for the 
maintenance of the optimal level of both cations in cells and 
in interstitial fluids. 
(e) Nucleoside Diphosphatase (NDPase) 
  The activity of NDPase is commonly used as one of the 
marker enzymes for the demonstration of the endoplasmic 
reticulum (ER) in several types of cells [60]. In the mouse 
central nervous system, the reaction product appeared in neu-
rons, astrocytes and oligodendrocytes in the cisternae of the 
ER or only in the trans-elements of the Golgi apparatus [88]. 
3.2. Glycocalyx 
  The glycocalyx is a negatively charged, surface coat of 
proteoglycans, glycosaminoglycans, and adsorbed plasma 
proteins lining the luminal surface of the endothelium [52]. 
Some researchers have put forward the concept that the en-
dothelial glycocalyx contributes to the vasculoprotective 
effects of the vessel wall [59]. This layer has also been 
shown to be involved in maintaining vascular permeability 
[35]. The endothelial glycocalyx can be evaluated by meas-
uring the binding capacity of cationized ferritin on the lumi-
nal endothelial surface [83] (Fig. 1B). In addition, the glyco-
calyx harbours a wide array of enzymes that might contribute 
to its vasculoprotective effect. Extracellular superoxide dis-
mutase, an enzyme that converts oxygen radicals to hydro-
gen peroxide, is bound to heparan sulphate proteoglycans 
within glycocalyx [47]. Damage to the glycocalyx is accom-
panied by increased shedding of extracellular superoxide 
dismutase, which is probably related to the decreased avail-
ability of heparan sulphate binding sites. The glycocalyx 
damage shifts the balance towards a pro-oxidant state. These 
observations are of particular interest because altered vascu-
lar permeability, attenuated nitric oxide bioavailability, and 
redox dysregulation are the earliest characteristics of athero-
genesis [48]. In addition, a disappearance of the glycocalyx 
is expected to be followed by the exposure of adhesion mole-
cules on ECs and subsequent leukocyte rolling, tethering and 
transmigration, which are critical in the course of athero-
genesis [48]. This evidence suggests that the intact glycoca-
lyxis necessary for the maintenance of normal vascular func-
tion, and that disruption of glycocalyx by atherogenic stimuli 
increases the vascular vulnerability to atherogenesis. Moreo-
ver, it is known that endothelial glycocalyx is disturbed in 
various types of vascular diseases [59]. It is also known that 
inflammation induces glycocalyx shedding [55]. One of the 
most common chemokines expressed in the CNS during in-
flammation is monocyte chemoattractant protein-1 [25]. 
High chemokine expression is found in many pathological 
settings accompanied by inflammation, providing a chemoat-
tractant gradient for leukocyte influx to the brain [56,67].  
4. TRANSPORTERS IN BRAIN MICROVASCULA-
TURE 
  The blood-to-brain influx transporters supply hydrophilic 
nutrients and other essential molecules such as glucose [63], 
lactate/monocarboxylates [22], and creatine [61]. In addition, 
L-tyrosine,  L-tryptophan, and L-histidine are precursors of 
neurotransmitters, and are transported from the blood to the 
brain via a Na
+-independent neutral amino acid transporter 
(system L) at the BBB [62]. The system L is potentially im-
portant for drug delivery to the brain. L-Dopa is transported 
across the BBB by system L, and is ready biotransformed in 
the brain to dopamine [32]. On the other hand, there are sev-
eral kinds of efflux transporters at the BBB such as ATP-
binding cassette (ABC) transporters, organic anion transport 
(OAT) systems, aminoacid transport systems, and so on [62]. 
  Major representatives of the ABC efflux transporters are 
the multidrug resistance protein (MDR), multidrug resistance 
associated protein (MRP), and breast cancer resistance pro-
tein [80]. P-glycoprotein (P-gp), which belongs to the MDR 
family, preferentially transports cationic and /or zwitterionic 
compounds as substrates, whereas the MRP family preferen-
tially transports anionic compounds, although there is some 
overlap between them [36]. Newly discovered categories of 
transporters are the OAT family, the organic cation trans-
porter (OCT) family, the organic cation transporter novel 
type (OCTN)/carnitine transporter family [1,74], and the 
monocarboxylic acid transporter (MCT) family [64], which 
is expected to be responsible for the transport of some or-
ganic anions from the brain to the EC and/or from the EC to 
the blood [80]. In addition, the concentrative nucleoside 
transporter and equilibrative nucleoside transporter subfami-
lies have also detected in brain capillaries or brain capillary 
EC lines [3]. 
(a) P-gp 
<i> Function and Distribution of P-gp
  The multidrug resistance efflux transporter P-gp was the 
plasma membrane protein first demonstrated in cancer cells 
by reducing intracellular levels of chemotherapeutic drugs 
[49]. However, P-gp is also expressed in various normal tis-
sues such as the liver, kidney, intestine, and brain, where it 
functions to protect the tissue against potentially toxic ex-
ogenous compounds [8,29,69]. In addition, it is known that 
P-gp is identified not only in normal epithelial cells with 
secretory/excretory functions but also in the ECs of the capil-
lary blood vessels in the brain [70] and the testis [53]. Until 
quite recently, P-gp in the brain had been thought to be pri-
marily located in the apical (luminal) membrane of capillary 
ECs that form the BBB and to become part of the mecha-
nisms involved in protecting the brain from xenobiotics 
[4,23,68]. A recent study using a new polyclonal antibody 
against P-gp [71] demonstrated dual expression of P-gp at 
astrocytes and the endothelium in normal primate brains. In 
addition, Bendayan et al. [5] recently reported that P-gp lo-
calized to both the luminal and abluminal membranes of 
capillary ECs, as well as in adjacent pericytes and astrocytes 
(Fig.  2). These authors reported that P-gp was distributed 
along the nuclear envelope, in the caveolae, cytoplasmic 
vesicles, Golgi complex, and rough endoplasmic reticulum. 
They stated that this glycoprotein might regulate drug trans-
port processes in the CNS at both the cellular and subcellular 
levels. 
<ii> P-gp Related Drug-Drug Interaction
  P-gp substrates include not only a wide variety of anti-
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Fig. (2). (A) Hypothetical transcytotic routes through ECs of the 
BBB and membrane events associated with endocytic processes are 
represented. Direct transendothelial vesicular transport or an indi-
rect route through the endosomal compartment (E) may apply to the 
receptor-mediated transcytosis of blood-borne ligands. Some endo-
cytic vesicles derived from the luminal surface membranes are 
likely directed to endosomes that give rise to exocytic vesicles. 
Macromolecules entering the endothelium by adsorptive endocyto-
sis are channeled to endosomes and either direcly or indirectly to 
the inner saccule of the Golgi complex (G); this Golgi saccule is 
responsible for packaging macromolecules for exocytosis at the 
abluminal and luminal faces of the endothelium. Fluid-phase mac-
romolecules and some macromolecules taken into the endothelium 
by receptor-mediated and adsorptive endocytic processes are di-
rected to endosomes (E) and lysosomes (L). The macromolecules 
deposited in lysosomes are enzymatically degraded rather than tran-
scytosed. The multidrug resistance efflux transporter P-gp is shown 
at the luminal and abluminal membranes of the endothelial cyto-
plasm. (B) A rat brain was removed after perfusion with physio-
logical saline and immersion-fixed with 4% paraformaldehyde in 
0.1M phosphate buffer (PB). The brain tissue was embedded in LR 
White resin after additional fixation in 1% glutaraldehyde in 0.1M 
PB for 1 hour. Ultrathin sections were stained with anti-P-gp anti-
body, followed by incubation in a solution of anti-mouse IgG anti-
body conjugated with colloidal gold particles of 10 nm diameter 
(EY Laboratories, CA), diluted with phosphate buffered saline 
(1:25), for 1 h at RT. The ultrathin secions were stained with uranyl 
acetate and Reynold’s lead citrate, and were examined in a JEM-
1200EX electron microcope (JEM, Tokyo, Japan). Labeling by 10-
nm gold particles conjugated with the antibody against P-gp is 
found in the cytoplasm including the luminal (long arrows) and 
abluminal (short arrows) membranes of the ECs, and the basal lam-
ina. The scale bar indicates 500 nm.
pounds, such as immunosuppressive agents, cardiac gly-
cosides, opioid analgesics, antibiotics, pesticides, antiepilep-
tics, antidepressants, and human immunodeficiency virus 
protease inhibitors [69]. Inhibition of P-gp can be achieved 
by antidepressants [91], suggesting the possibility that using 
a medicine together with an antidepressant may lead to an 
increase in the brain concentration of the medicine. It is also 
shown that at clinically relevant doses given orally, oxytetra-
cycline is able to saturate P-gp and, subsequently, the net 
absorption of other drugs increases [72]. In addition, the 
large number of psychoactive drugs that are substrates of P-
gp could be potentially involved in s significant number of 
drug-drug interactions regarding P-gp. Because of overlap-
ping substrates specificities between CYP3A4 and P-gp, 
many drug interactions may involved both CYP2A4 and P-
gp [50]. Therefore, it is important to distinguish CYP3A4-
mediated from P-gp-mediated inhibition in order to make 
appropriate interpretation of drug interaction data. 
<iii> P-gp and Neurodegenerative Disease
  P-gp deficiency induces an undesirable effect on the 
brain. It has been hypothesized that A proteins are depos-
ited in periarterial interstitial fluid drainage pathways of the 
brain, contributing significantly to cerebral amyloid angiopa-
thy in Alzheimer’s disease [92]. Vogelgesang et al. [87] re-
ported that A deposition occurred first in arterioles, where 
P-gp expression was primarily low, and disappeared com-
pletely with the accumulation of A proteins. In addition, 
Cirrito et al. [19] reported that P-gp deficiency at the BBB 
increased amyloid- deposition in a murine model of Alz-
heimer’s disease, suggesting that P-gp normally discharges 
A out of the brain or periarterial interstitial fluid, and that 
perturbation of A efflux directly affects A accumulation 
within the brain or perivascular areas. It was very recently 
reported that P-gp expression was increased in the BBB-
damaged vessels of a stroke-prone hypertensive rat [84]. It 
seems to be likely that the expression of P-glycoprotein in-
creases as a temporary physiological compensatory response 
in BBB-damaged vessels to discharge intracerebral or periar-
terial undesirable substances from the brain. These findings 
suggest that endothelial P-gp contributes to efflux of unde-
sirable substances from the brain or periarterial interstitial 
fluid. Concerning transendothelial transport of -amyloid 
protein, the receptor for advanced glycation end products 
(RAGE) is thought to be a primary transporter of -amyloid 
across the BBB into the brain from systemic circulation, 
while the low-density lipoprotein receptor-related protein 
(LRP)-1 mediates transport of -amyloid out of the brain 
[26,94]. RAGE versus LRP balance regulates Alzheimer 
amyloid  -peptide clearance through transport across the 
BBB [24]. Accordingly, it is reasonable to think that plural 
factors contribute to removal of -amyloid. In addition, BBB 
efflux function of the P-gp transport system was decreased at 
later disease stages of Parkinson’s disease, suggesting that 
the P-gp dysfunction contributes to neuronal damage due to 
increased accumulation of toxins, such as insoluble -
synuclein [2]. 
<iiii> P-gp and Vascular Abnormalities
  According to a paper reported by Widder et al. [93], the 
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crucial role in the genesis of multiple vascular abnormalities 
that accompany hypertension. Moreover, its presence is es-
sential for the hypertensive response to angiotension II. The 
findings suggest that the increased expression of P-gp in 
BBB-damage vessels may induce directly the BBB damage.  
(b) MRP 
  MRP1 is a member of the ATP-binding cassette super-
family and is expressed in non-P-gp expressing MDR cell 
lines [21]. Of the MRP family, MRP1, MRP3, and MRP5 are 
expressed in the BBB [37,43,66]. Since MRP is involved in 
extrusion of conjugated xenobiotics that may be harmful to 
the brain, some authors suggest that MRP1 and/or its closely 
related proteins are expressed at the luminal side of the brain 
capillaries [45,73]. However, this has not been proven ex-
perimentally.  
(c) OAT Family 
  OATs are multispecific organic anion transporters, the 
substrates of which include both endogenous (e.g. cyclic 
nucleotides, prostaglandins, urate) and exogenous anions. 
OAT1 and OAT3 were demonstrated to be present on the 
brushborder of the choroid plexus [76] and in an in vitro
BBB model of cultured mouse brain ECs [44], respectively. 
Various organic anions are proposed as substrates of OAT, 
such as p-aminohippurate, dicarboxylates, and -lactam an-
tibiotics. 
(d) OCT Family 
  OCTs transport a variety of cationic compounds, includ-
ingmonoamineneurotransmitters and classical organic cation 
transporter substrates such as tetraethylammonium, and cho-
line. Rat OCT3 and human OCT2 are expressed in the brain. 
It is thought that they participate in the regulation of neuro-
transmitters in neurons rather than at the BBB [80].  
  A new family of OCTNs has been also found [81]. The 
amino acid sequences of OCTNs show low, but significant, 
similarity to those of OCT and OAT family members. The 
OCTNs were initially thought to be organic cation transport-
ers. However, subsequent studies clarified that they physio-
logically functioned as sodium ion-dependent transporters 
for carnitine, which is important in the metabolism of fatty 
acids [58,79].  
(e) MCT Family 
  It is known that MCT1 mediates the transport of lactic 
acid and pyruvic acid [30]. The MCT1 gene was detected in 
rat brain capillaries by using a RT-PCR method [78]. The 
MCT1 protein was immunohistochemically detected at both 
luminal and abluminal membranes of the brain capillary ECs 
[31]. It is thought that the MCT1 at the BBB contributes to 
the regulation of energy substrates in the brain parenchyma. 
5. POTENTIAL PATHWAY OF BLOOD-BORNE 
COMPOUNDS INTO THE BRAIN 
  Mentioned above, the endothelial glycocalyx with ex-
tracellular enzymes covers the luminal surface of the ECs 
and accordingly works at the first line of the BBB. The ECs 
of brain capillaries are morphologically characterized with 
limited vesicular transcytosis and tight junctions. Enzymatic 
constituents in the endothelial cytoplasm of brain capillaries 
inactivate some substrates. The endothelial transcytosis in 
brain capillaries is limited to specific substrates because sev-
eral kinds of influx and efflux transporters are located at the 
BBB. In these ways, the BBB impedes the influx of intravas-
cular compounds from the blood to the brain. In order to 
work medicines on brain function, medicines should be 
transferred into the brain through the BBB, and the medi-
cines entering the brain should be escaped from discharge 
into the blood by the transporters or modification by the en-
zymes. Various trials for medicines to pass the BBB into the 
brain parenchyma have been performed.  
  Osmotic opening of TJs has been reported in several 
types of animal models [57], since the original reports by 
Broman and Olsson in the 1940s [18]. It is likely that re-
versible opening of TJs would be useful for delivery of 
medicines into the brain. It is also known that the intra-
arterial administration of alkylglycerols transiently increases 
the penetration of drugs and macromolecules across the 
BBB, suggesting that the administration of alkylglycerols 
could be a unique method for enhanced drug delivery to the 
brain and to brain tumors [27,46]. It is most likely that in-
creased lipophilicity of drugs makes transportation into the 
brain easy. Compounds bound to lectins are thought to be 
easily transported by adsorptive vesicular transport. En-
hanced vesicular transport can be used to deliver compounds 
into the brain. Transient inhibition of P-gp by medicines 
such as antidepressants may be useful for delivery of anti-
cancer drugs into the brain. It is likely that the manipulation 
of P-gp will be useful for delivery of medicines in brain and 
cerebrovascular diseases. If a targeted region is situated near 
one of the circumventricular organs (CVOs), the delivery of 
medicines to the region could be achieved via CVO capillar-
ies. There are extracellular pathways bypassing the BBB. 
Blood-borne proteins gaining extracellular access to non-
BBB sites can move not only within the cerebrospinal fluid 
of the subarachnoid space, but also into the brain paren-
chyma adjacent to each of the leaky sites [17]. It is possible 
in experimental animals that blood-borne macromolecules 
escaping the subfornical organ, a BBB-free area, have ready 
access not only to the white matter of the corpus callosum 
[17], but also to the hippocampus [82]. A drainage pathway 
through the subarachnoid spaces of olfactory nerves from the 
brain to deep cervical lymph nodes has been also proposed 
by Bradbury et al. [10]. Accordingly, nasally inhaled medi-
cines can affect parts of the brain through the subarachnoid 
spaces of olfactory nerves. 
  In addition, it has been investigated in experimental ani-
mals whether the treatment of brain diseases is possible by 
using gene targeting technology that delivers the gene across 
the BBB after i.v. administration of nonviral formulation of 
the gene [75]. In the experiment, the plasmid DNA was tar-
geted to brain with pegylated immunoliposomes using a tar-
geting ligand such as an antibody to transferrin receptor or 
insulin receptor. 
  Thus, detailed information on the BBB is necessary and 
useful to plan a strategy and develop therapies against vari-
ous brain and vascular diseases.  Mechanisms of the Penetration of Blood-Borne Substances  Current Neuropharmacology, 2009, Vol. 7, No. 2    147
ABBREVIATIONS 
ABC =  ATP-binding  cassette 
ACPase = Acid  phosphatase 
ALPase = Alkaline  phosphatase 
AJ =  Adherens  junction 
ATPase = Adenosine  triphosphatase 
BBB =  Blood-brain  barrier 
CNS =  Central  nervous  system 
CSF =  Cerebrospinal  fluid 
CVO =  Circumventricular  organ 
EC =  Endothelial  cell 
ER =  Endoplasmic  reticulum 
MCT  =  Monocarboxylic acid transporter 
MDR  =  Multidrug resistance protein 
MRP  =  Multidrug resistance associated protein 
5’-N =  5’-Nucleotidase 
NDPase = Nucleoside  diphosphatase 
OAT  =  Organic anion transporter 
OCT  =  Organic cation transporter 
OCTN  =  Organic cation transporter novel type 
P-gp =  P-glycoprotein 
TJ =  Tight  junction 
ZO =  Zonula  occludens 
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